J&J sues Amgen over cancer drug sales tactics

10/14/2005 | NYTimes.com

Johnson & Johnson filed an antitrust suit alleging Amgen used sales tactics to force cancer clinics to buy its Aranesp rather than J&J's Procrit, drugs used to treat chemotherapy-related anemia. The suit notes U.S. sales of the two drugs are expected to reach $2.8 billion this year. An Amgen spokeswoman said, "We believe the allegations are not legitimate and we intend to fight this."

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX